Aldeyra Therapeutics (FRA:137) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aldeyra Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aldeyra Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Aldeyra Therapeutics's long-term debt to total assets ratio declined from Mar. 2023 (0.09) to Mar. 2024 (0.00). It may suggest that Aldeyra Therapeutics is progressively becoming less dependent on debt to grow their business.

Aldeyra Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Aldeyra Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aldeyra Therapeutics LT-Debt-to-Total-Asset Chart

Aldeyra Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.19

0.14

0.07

0.08

Aldeyra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.09	0.07	0.02	-	-

Aldeyra Therapeutics LT-Debt-to-Total-Asset Calculation

Aldeyra Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.249	/	136.016
	=

Aldeyra Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0.19	/	129.998
	=

Aldeyra Therapeutics (FRA:137) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aldeyra Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Aldeyra Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Aldeyra Therapeutics (FRA:137) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (FRA:137) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ALDX:USA 137:Germany

Address

131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421

Website

https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics (FRA:137) Headlines

No Headlines